Free shipping on all orders over $ 500

Denintuzumab-MMAF

Cat. No. M58983

All AbMole products are for research use only, cannot be used for human consumption.

Denintuzumab-MMAF Structure
Synonym:

Anti-CD19 Reference Antibody

Size Price Availability Quantity
100ug USD 480 In stock
1mg USD 1280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >99%, Endotoxin < 1 EU/µg
  • COA
  • MSDS
Biological Activity

Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used in the research of acute lymphoblastic leukemia.

Immobilized human EGFR His at 2 ug/mL can bind denintuzumab-MMAF, the EC50 is 0.01985 ug/mL.

Chemical Information
Solubility (25°C) For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml.
Storage Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles.
Related Antibody-Drug Conjugates (ADCs) Products
Talacotuzumab-MMAE

Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody.

Enfortumab vedotin-ejfv

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker.

Vandortuzumab vedotin

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

Farletuzumab MMAE

Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE.

Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Denintuzumab-MMAF, Anti-CD19 Reference Antibody supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.